Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spectral.DNC-N is a high-performance topical hair density serum developed by DS Laboratories (a subsidiary of Divine Skin) for the treatment of hair thinning and the improvement of hair density. The product's primary active ingredient is 5% Nanoxidil, a proprietary molecular compound with a lower molecular weight than minoxidil, designed to enhance absorption and efficacy while minimizing side effects. The multi-active formulation also includes caffeine, adenosine, azelaic acid, copper tripeptides, and retinol. These components are delivered via the company's proprietary Nanosome Delivery System, which encapsulates the ingredients in microscopic liposomes to ensure deep penetration and sustained release. It is marketed as a drug-free cosmetic solution that increases the appearance of hair thickness and volume, typically showing results within 90 to 180 days of twice-daily application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Spectral.DNC-N.